OncoMatch/Clinical Trials/NCT06437977
Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
Is NCT06437977 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Toripalimab for stage ii-iii non-small cell lung cancer.
Treatment: Toripalimab — This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Disease stage
Required: Stage II, IIIA, IIIB (N2) (AJCC version 8)
Excluded: Stage IIIC
resectable, stage II, IIIA, IIIB (N2) (AJCC staging system, version 8) NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antitumor therapy
Previous treatment with systemic antitumor therapy for early NSCLC, including investigational product
Cannot have received: anti-PD-1/PD-L1 or other targeted T cell receptor therapy
Previous use of PD-1/PD-L1 agent or the drug acting on another targeted T cell receptor (e.g., CTLA-4, OX-40)
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 109/l, platelet count ≥ 80 × 109/l, hemoglobin ≥9 g/dl
Kidney function
serum creatinine ≤ 1.5 × uln or serum creatinine clearance rate ≥ 60 ml/min; blood urea nitrogen ≤ 200mg/l
Liver function
total bilirubin ≤ 1.5 × uln, alt and ast ≤ 1.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify